Topics

Immunomedics Resubmits its BLA to the FDA for Accelerated Approval of Sacituzumab Govitecan for Treatment of Metastatic Triple-Negative Breast Cancer

10:14 EST 4 Dec 2019 | Speciality Pharma Journal

MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with …

Original Article: Immunomedics Resubmits its BLA to the FDA for Accelerated Approval of Sacituzumab Govitecan for Treatment of Metastatic Triple-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Immunomedics Resubmits its BLA to the FDA for Accelerated Approval of Sacituzumab Govitecan for Treatment of Metastatic Triple-Negative Breast Cancer"

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...